Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMN19QP)

Drug Name
4-amino-N-(4-iodophenyl)benzenesulfonamide Drug Info
Synonyms
6965-75-9; NSC63371; 4-amino-N-(4-iodophenyl)benzenesulfonamide; 4-amino-n-(4-iodo-phenyl)-benzenesulfonamide; Benzenesulfonamide, 4-amino-N-(4-iodophenyl)-; 4-amino-N-(4-iodophenyl)benzene-1-sulfonamide; Benzenesulfonamide,4-amino-N-(4-iodophenyl)-; NSC 63371; Enamine_003086; AC1Q6VVM; AC1Q51XD; AC1L6LA2; AC1Q51XC; 4-IODOSULFANILANILIDE; CHEMBL227416; CTK5D0764; DTXSID00219913; MolPort-001-833-979; HMS1402M06; ZINC537958; NSC-63371; STK063720; AKOS000115972; NE11209; MCULE-7780071880; KB-290010; EN300-02869; SR-01000033730
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
247908
CAS Number
CAS 6965-75-9
TTD Drug ID
DMN19QP

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Prostaglandin G/H synthase 2 (COX-2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [2]
Naproxen DMZ5RGV Bursitis Approved [3]
Etodolac DM6WJO9 Osteoarthritis FA00-FA05 Approved [4]
Indomethacin DMSC4A7 Bursitis Approved [5]
Celecoxib DM6LOQU Dysmenorrhea GA34.3 Approved [6]
Nabumetone DMAT2XH Osteoarthritis FA00-FA05 Approved [7]
Rofecoxib DM3P5DA Osteoarthritis FA00-FA05 Approved [8]
Flurbiprofen DMGN4BY Osteoarthritis FA00-FA05 Approved [9]
Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 Hypertriglyceridemia 5C80.1 Approved [10]
Aminosalicylic Acid DMENSL5 Crohn disease DD70 Approved [5]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostaglandin G/H synthase 2 (COX-2) TTVKILB PGH2_HUMAN Inhibitor [1]

References

1 Analgesic agents without gastric damage: design and synthesis of structurally simple benzenesulfonanilide-type cyclooxygenase-1-selective inhibitors. Bioorg Med Chem. 2007 Jan 15;15(2):1014-21.
2 Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009 Sep;28(2):239-44.
3 Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
4 Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. Intern Med. 2007;46(13):1055-8.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6 Pfizer. Product Development Pipeline. March 31 2009.
7 Renal effects of nabumetone, a COX-2 antagonist: impairment of function in isolated perfused rat kidneys contrasts with preserved renal function in vivo. Exp Nephrol. 2001;9(6):387-96.
8 Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
9 Flurbiprofen, a cyclooxygenase inhibitor, protects mice from hepatic ischemia/reperfusion injury by inhibiting GSK-3 signaling and mitochondrial permeability transition.Mol Med.2012 Sep 25;18:1128-35.
10 Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.